IceCure gets favorable FDA AdCom vote for ProSense System [Seeking Alpha]
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: Seeking Alpha
for its ProSense System for the destruction of early-stage breast cancer tumors using cryoablation technology. The committee voted 9 to 5 that the benefits of the system outweighed the risks. Three of the five that voted against also said that they would be in favor if the FDA applied adequate controls, according to a statement. The Israeli company is seeking to have the system approved for the treatment of early-stage low risk invasive breast cancer with cryoablation and adjuvant endocrine therapy. IceCure said it expects to make a decision on whether to authorize the product in Q1 2025. More on IceCure Medical IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript FDA AdComm to discuss IceCure's ProSense on Nov. 7 Seeking Alpha's Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical Recommended For You Comments Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual MeetingPR Newswire
- IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results [Yahoo! Finance]Yahoo! Finance
- IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study ResultsPR Newswire
- IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.MarketBeat
ICCM
Earnings
- 5/28/24 - In-Line
ICCM
Analyst Actions
- 11/27/24 - HC Wainwright
ICCM
Sec Filings
- 12/5/24 - Form 6-K
- 11/26/24 - Form 6-K
- 11/25/24 - Form 6-K
- ICCM's page on the SEC website